drug-discovery

To assess drug-likeness, evaluate molecules against Lipinski's Rule of Five and Veber's rules to predict oral bioavailability. This automated screening calculates molecular properties to identify suitable lead compounds for pharmaceutical research.

Yes, you can query the ChEMBL database to find bioactive compounds by target or activity. This bioactive compound search automates retrieval of pharmacological data, streamlining the identification of molecules with desired biological activity profiles.

Access OpenFDA data to identify potential drug-drug interactions and reported adverse events. This safety and interaction lookup allows researchers to cross-reference candidate molecules with known adverse event profiles during lead compound prioritization.

Yes, standard Python 3 and curl are required to execute API-driven queries for scientific data analysis. These dependencies facilitate integrating data from ChEMBL, PubChem, OpenFDA, and OpenTargets to automate pharmaceutical research workflows.

The best way to screen candidates is automating retrieval of bioactivity data, calculating molecular properties, and assessing drug-likeness. This process evaluates ADMET profiling and Lipinski violations to prioritize lead compounds for medicinal chemistry research.